The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | ADAURA: osimertinib post-tumor resection in NSCLC
Roy Herbst
• 26 May 2020
Roy Herbst, MD, PhD, FACP, FASCO, Yale University, New Haven, CT, talks about the data from the ADAURA study (NCT02511106) in which patients with stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) were treated with osimertinib as adjuvant therapy after complete tumor resection. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
